sub_visual

Announcement Information

Num| Date| Title| Submitter
10 2020.08.03 Material Management Information related to Judgment of Investment(당뇨병성 신증 치료제 APX-115의 유럽 임상 2상 시험 계획(IND) 승인) Aptabio Therapeutics Inc.
9 2020.06.19 Other Management Information(Obtainment of Patent)(Voluntary Disclosure)(3-페닐-4-프로필-1-(피리딘-2-일)-1H-피라졸-5-올 염산염의 신규 결정형 고체화합물) Aptabio Therapeutics Inc.
8 2020.06.12 Material Management Information related to Judgment of Investment(당뇨병성 신증 치료제 APX-115의 유럽 임상 2상 시험 계획(IND) 승인) Aptabio Therapeutics Inc.
7 2020.06.10 Material Management Information related to Judgment of Investment(당뇨병성 신증 치료제 APX-115의 유럽 임상 2상 시험 계획(IND) 승인) Aptabio Therapeutics Inc.
6 2020.06.04 Other Management Information(Obtainment of Patent)(Voluntary Disclosure)(간질환 치료제) Aptabio Therapeutics Inc.
5 2020.05.20 Material Management Information related to Judgment of Investment(당뇨병성 신증 치료제 APX-115의 유럽 임상 2상 시험 계획(IND) 승인) Aptabio Therapeutics Inc.
4 2020.04.28 Other Management Information(Obtainment of Patent)(Voluntary Disclosure)(신증 진단용 마커로서의 SH3YL1의 용도) Aptabio Therapeutics Inc.
3 2020.04.08 Additional Listing(주식매수선택권행사) Aptabio Therapeutics Inc.
2 2020.04.02 Other Management Information(Obtainment of Patent)(Voluntary Disclosure) Aptabio Therapeutics Inc.
1 2020.03.27 Outcome of Annual Shareholders` Meeting Aptabio Therapeutics Inc.
2020.08.03 Aptabio Therapeutics Inc.
Material Management Information related to Judgment of Investment(당뇨병성 신증 치료제 APX-115의 유럽 임상 2상 시험 계획(IND) 승인)
2020.06.19 Aptabio Therapeutics Inc.
Other Management Information(Obtainment of Patent)(Voluntary Disclosure)(3-페닐-4-프로필-1-(피리딘-2-일)-1H-피라졸-5-올 염산염의 신규 결정형 고체화합물)
2020.06.12 Aptabio Therapeutics Inc.
Material Management Information related to Judgment of Investment(당뇨병성 신증 치료제 APX-115의 유럽 임상 2상 시험 계획(IND) 승인)
2020.06.10 Aptabio Therapeutics Inc.
Material Management Information related to Judgment of Investment(당뇨병성 신증 치료제 APX-115의 유럽 임상 2상 시험 계획(IND) 승인)
2020.06.04 Aptabio Therapeutics Inc.
Other Management Information(Obtainment of Patent)(Voluntary Disclosure)(간질환 치료제)
2020.05.20 Aptabio Therapeutics Inc.
Material Management Information related to Judgment of Investment(당뇨병성 신증 치료제 APX-115의 유럽 임상 2상 시험 계획(IND) 승인)
2020.04.28 Aptabio Therapeutics Inc.
Other Management Information(Obtainment of Patent)(Voluntary Disclosure)(신증 진단용 마커로서의 SH3YL1의 용도)
2020.04.08 Aptabio Therapeutics Inc.
Additional Listing(주식매수선택권행사)
2020.04.02 Aptabio Therapeutics Inc.
Other Management Information(Obtainment of Patent)(Voluntary Disclosure)
2020.03.27 Aptabio Therapeutics Inc.
Outcome of Annual Shareholders` Meeting